Nevertheless, the FcRn blockage certainly introduces therapeutic possibilities for other autoantibody- and/or T-cell-mediated autoimmune disorders, such as chronic inflammatory demyelinating polyneuropathy, myositis and multifocal motor neuropathy, which have been included in future studies by the efgartigimod company, argenx [61]. Here, FCGRT is linked to chronic inflammatory demyelinating polyradiculoneuropathy.